Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has announced that Schering-Plough KK, the company's country operation in Japan, has received marketing approval for Nasonex nasal spray 50mcg for the treatment of allergic rhinitis in adult patients.
Subscribe to our email newsletter
Schering-Plough’s Nasonex is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. Nasonex is said to be the first intranasal steroid to be approved in Japan for once-daily administration.
Nasonex is currently approved in over 100 countries worldwide and is anticipated to be available in Japan in 2008 fall.
Robert Spiegel, chief medical officer of Schering-Plough Research Institute, said: “Nasonex provides physicians with an important treatment option for the relief of nasal allergy symptoms, especially for those patients looking for the convenience of a once-daily treatment.”